KR20210031853A - 인간 제대 조직-유래 중간엽 간질 세포를 사용한 자폐 스펙트럼 장애 치료 방법 - Google Patents

인간 제대 조직-유래 중간엽 간질 세포를 사용한 자폐 스펙트럼 장애 치료 방법 Download PDF

Info

Publication number
KR20210031853A
KR20210031853A KR1020207031742A KR20207031742A KR20210031853A KR 20210031853 A KR20210031853 A KR 20210031853A KR 1020207031742 A KR1020207031742 A KR 1020207031742A KR 20207031742 A KR20207031742 A KR 20207031742A KR 20210031853 A KR20210031853 A KR 20210031853A
Authority
KR
South Korea
Prior art keywords
hct
msc
months
cells
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207031742A
Other languages
English (en)
Korean (ko)
Inventor
조안느 커츠버그
제럴딘 도슨
제시카 선
Original Assignee
듀크 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68101425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20210031853(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 듀크 유니버시티 filed Critical 듀크 유니버시티
Publication of KR20210031853A publication Critical patent/KR20210031853A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Educational Technology (AREA)
  • Hospice & Palliative Care (AREA)
KR1020207031742A 2018-04-04 2019-04-04 인간 제대 조직-유래 중간엽 간질 세포를 사용한 자폐 스펙트럼 장애 치료 방법 Ceased KR20210031853A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652722P 2018-04-04 2018-04-04
US62/652,722 2018-04-04
PCT/US2019/025716 WO2019195506A1 (en) 2018-04-04 2019-04-04 Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells

Publications (1)

Publication Number Publication Date
KR20210031853A true KR20210031853A (ko) 2021-03-23

Family

ID=68101425

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031742A Ceased KR20210031853A (ko) 2018-04-04 2019-04-04 인간 제대 조직-유래 중간엽 간질 세포를 사용한 자폐 스펙트럼 장애 치료 방법

Country Status (12)

Country Link
US (1) US12491210B2 (https=)
EP (1) EP3773486B1 (https=)
JP (1) JP2021520380A (https=)
KR (1) KR20210031853A (https=)
CN (1) CN112351785A (https=)
AU (1) AU2019247210A1 (https=)
BR (1) BR112020020295A2 (https=)
CA (1) CA3096033A1 (https=)
ES (1) ES2968823T3 (https=)
IL (1) IL277733B2 (https=)
SG (1) SG11202009805PA (https=)
WO (1) WO2019195506A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113057969A (zh) * 2021-03-09 2021-07-02 吴志新 一种间充质干细胞对儿童自闭症临床应用实验方法
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
US9347956B2 (en) 2010-12-16 2016-05-24 Autism Biotech Limited Biomarker and uses thereof in diagnosis, treatment of autism
AU2017235446A1 (en) 2016-03-16 2018-11-08 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy
US20170296588A1 (en) * 2016-04-19 2017-10-19 AngioStem, Inc. Mesenchymal stem cells derived from placental sources
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
US10987381B2 (en) 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis

Also Published As

Publication number Publication date
CA3096033A1 (en) 2019-10-10
EP3773486A1 (en) 2021-02-17
BR112020020295A2 (pt) 2021-01-12
IL277733B1 (en) 2024-06-01
AU2019247210A1 (en) 2020-11-05
EP3773486B1 (en) 2023-12-06
IL277733A (en) 2020-11-30
US20210128631A1 (en) 2021-05-06
SG11202009805PA (en) 2020-11-27
IL277733B2 (en) 2024-10-01
US12491210B2 (en) 2025-12-09
WO2019195506A1 (en) 2019-10-10
JP2021520380A (ja) 2021-08-19
ES2968823T3 (es) 2024-05-14
CN112351785A (zh) 2021-02-09
EP3773486A4 (en) 2021-12-15
EP3773486C0 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
Sun et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder
Dawson et al. Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial
Chez et al. Safety and observations from a placebo-controlled, crossover study to assess use of autologous umbilical cord blood stem cells to improve symptoms in children with autism
Selden et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis
Olin et al. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4+ IL17+ response
Schlosser-Brandenburg et al. Influence of nutrition and maternal bonding on postnatal lung development in the newborn pig
US12491210B2 (en) Methods of assessing and treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
US11813294B2 (en) Methods for the treatment of autism spectrum disorders
Tai-MacArthur et al. The theoretical basis of in utero hematopoietic stem cell transplantation and its use in the treatment of blood disorders
AU2019247383B2 (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
HK40045701A (en) Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
Shamim et al. The promise of autologous and allogeneic cellular therapies in the clinical trials of autism spectrum disorder
Gesundheit et al. Mesenchymal stromal cell treatment alleviates autism spectrum disorder symptoms: a case report
US20200016213A1 (en) Methods of Treating Cerebral Palsy Using High Dose Allogeneic Umbilical Cord Blood
Pek et al. 487 Parents perceptions of diagnostic process and treatment in children with developmental disabilities
Fahey et al. Safety and Feasibility of Autologous Cord Blood Infusion for Cerebral Palsy: A Case Report With Ethical and Translational Considerations
Kinsella Haematopoietic Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis Type IIIA
Alvarado Oligodendrocytes in autoimmune demyelination: Role of the potassium channel Kv1. 4 and interaction with T helper cells
HK40044465A (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
Mello et al. Giant cell arteritis: a diagnostic challenge in an older adult
Babinski Allogeneic Mesenchymal Stromal Cell Infusions Are Safe and Effective in Children with Autism Spectrum
González Alvarado Oligodendrocytes in autoimmune demyelination: Role of the potassium channel Kv1. 4 and interaction with T helper cells
Gauthier Mesenchymal Stem Cell Transplantation: A Novel Approach to Treating Progressive Neurological Diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201103

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220401

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250205

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250409

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D